AstraZeneca’s Opposition to Motion to Intervene - AstraZeneca v. Cochran (March 12, 2021)

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ASTRAZENECA PHARMACEUTICALS LP,

Plaintiff,

v.                                                              C.A. No. 21-27 (LPS)

NORRIS COCHRAN, et al.,                    ADMINISTRATIVE PROCEDURE ACT                             
                                                                 REVIEW OF AGENCY DECISION
Defendants.
                                                             
 

PLAINTIFF’S OPPOSITION TO PROPOSED INTERVENORS’
MOTION TO INTERVENE

Related Resources

Letter/Comment
Public
AHA, others express support of the 340B federal drug pricing program and strongly encourage Congress to protect the program as they consider broader changes to…
Guides/Reports
Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990…
Fact Sheets
Public
The COVID-19 pandemic has altered hospitals’ payer mix, which for some hospitals has temporarily lowered their disproportionate share hospital (DSH) percentage…
Special Bulletin
Public
Download the AHA Special Bulletin: CMS Issues Hospital Outpatient/ASC Proposed Rule, Including Modifications to Price Transparency Rule
Advancing Health Podcast
Public
Columbus, Ohio-based Mount Carmel Health System goes beyond the walls of its hospital to serve its community and patients through programs such as Street…
Letter/Comment
Public
Amy Bricker President Express Scripts PBM 1 Express Way Saint Louis, MO 63121 Dear Ms. Bricker: